Ningbo Menovo Pharmaceutical Co., Ltd. Class A

Ningbo Menovo Pharmaceutical Co., Ltd. Class A

SSSE:603538
19.14
CNY
-0.43
(-2.20%)
0.34EPS
83.11P/E
9.72BMarket Cap
Apr 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.39
3.02
2.84
2.75
2.29
3.02
4.16
4.15
4.29
4.94
3.75
4.55
5.04
5.69
Basic EPS, GAAP
0.33
0.35
0.37
0.37
0.17
0.34
0.53
0.54
0.49
1.15
0.04
0.22
0.34
0.34
Free Cash Flow per Basic Share
- -
0.14
0.34
0.04
-0.02
-0.9
-0.52
-0.31
-1.05
-1
-0.65
-0.27
0.15
- -
Dividend per Share
0.13
0.05
0.01
0.01
0.02
0.14
0.18
0.14
0.05
0.17
0.18
0.08
0.09
0.04
Book Value per Share
2.2
2.53
2.89
3.27
3.96
4.1
4.66
5.35
5.92
6.98
7.02
7.16
7.56
8.64
Tangible Book Value per Share
1.75
2.28
2.58
2.75
3.58
3.33
3.86
4.54
5.16
6.4
6.33
6.39
6.8
7.94
Basic Weighted Avg Shares
210
211
210
210
265
281
284
288
293
295
324
302
298
321
Sales/Revenue/Turnover
502
636
597
578
605
849
1,180
1,193
1,258
1,457
1,216
1,373
1,503
1,827
Operating Margin (%)
16.9
15.9
12.92
17.13
12.33
12.39
18.33
16.06
14.96
16.67
6.94
10.56
13.35
12.17
Depreciation Expense
- -
26
30
32
32
50
64
88
99
102
118
134
136
- -
Net Income, GAAP
69
73
77
79
45
96
151
156
143
339
12
67
102
110
Effective Tax Rate (%)
18.09
16.66
19.08
19.06
22.4
1.59
14.12
21.12
12.33
4.28
- -
12.55
18.23
23.88
Profit Margin (%)
13.75
11.43
12.9
13.64
7.38
11.35
12.79
13.07
11.33
23.26
0.95
4.87
6.8
6.04
Working Capital
-38
152
138
133
437
294
260
26
556
532
381
385
700
593
LT Debt
- -
- -
- -
- -
- -
108
123
135
755
706
760
664
690
15
Total Equity
487
564
646
731
1,163
1,340
1,569
1,775
1,979
2,173
2,186
2,291
2,451
3,031
Return on Invested Capital (%)
10.54
10.96
10.5
10.77
4.67
6.92
8.05
6.8
5.62
11.58
- -
2.27
2.88
- -
Return on Capital (%)
10.31
10.72
10.51
10.14
4.05
6.7
7.97
7.17
5.16
10.17
- -
2.8
3.49
- -
Return on Common Equity (%)
15.55
14.56
13.44
12.12
4.95
8.33
11.78
10.65
8.6
17.67
0.55
3.12
4.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
751
730
776
LT Borrowings
544
40
5
LT Finance Leases
12
11
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
309
340
340
Market Capitalization
9,018
7,903
9,719

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,050
2,174
2,196
Cash, Cash Equivalents & STI
642
643
580
Accounts Receivable, Net
320
440
487
Inventories
921
933
908
Total Current Liabilities
1,415
1,523
1,603
Payables & Accruals
- -
- -
- -
ST Debt
751
730
776
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.14%
6.73%
6.96%
Free Cash Flow
373.07%
0.17%
-155.56%
Net Income, GAAP
69.69%
112.44%
53.02%
Sales/Revenue/Turnover
10.9%
5.41%
9.49%
Total Cash Common Dividend
108.22%
33.15%
14.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
263
345
341
424
1,373
2025
276
401
- -
386
1,503
2026
338
521
582
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.02
0.15
0.01
0.22
2025
0.07
0.09
- -
0.02
0.34
2026
0.1
0.1
0.12
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
0.01
0.04
0.08
2025
0.03
0.05
- -
- -
0.09
2026
0.03
- -
- -
- -
- -

Company Description

CEO
Cheng Zhi Yao
Full Time Employees
2,370
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building1,Ningbo R&D Park Ningbo ZH China 315048
IPO Date
Apr 7, 2017
Business
Ningbo Menovo Pharmaceutical Co., Ltd. Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) researches, develops, produces and sells pharmaceutical products including active pharmaceutical ingredients (APIs), intermediates and finished dosage forms; its core offerings encompass cardiovascular treatments such as Valsartan, Losartan, Perindopril, Rosuvastatin Calcium and Atorvastatin Calcium; central nervous system medications including Pregabalin and Clopidogrel; as well as products for antiviral, hypoglycemic, gastrointestinal, respiratory, antitumor, anti-infection, digestive and geriatric applications like Apixaban Tablets, Lisinopril Tablets, Co-dergocrine Mesylate Tablets and Aminophylline Tablets. Founded in 2004 and headquartered in Ningbo City, Zhejiang Province, China, the company operates primarily in China with subsidiaries and facilities in Anhui and Zhejiang provinces, a Sino-European joint venture, provincial research institutes, and offices in India, the US and Europe; it serves domestic and international markets, particularly Europe as one of China's top exporters of characteristic APIs, and holds recognition as a top 20 CDMO enterprise in China for multiple years. Menovo maintains a fully integrated industrial chain for R&D, production and commercialization of its products, bolstered by rigorous quality, EHS management and large-scale manufacturing capabilities that support long-term partnerships with global pharmaceutical firms; it provides CDMO services encompassing contract development, manufacturing and one-stop platforms. In recent developments, the company suspended its high-end preparation project in July 2024 amid market shifts, centralized procurement pressures and product saturation, opting to re-evaluate investments and actively seek partners for high-end formulations while deepening research into industry trends; it completed full acquisition of the remaining 49% stake in Xuancheng Menovo Pharmaceutical Co., Ltd. in 2022 for approximately CNY 151.6 million, enhancing its preparation capabilities.